Sociedad Americana de Hirudoterapia

Comparison of Outcomes in Patients Requiring Mechanical Circulatory Support Who Received Cangrelor in Addition to Anticoagulation Versus Anticoagulation Alone

Research article published in Journal of cardiothoracic and vascular anesthesia (2024)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studyEnsayos clínicosDesarrollo de fármacosSeguridad y control de infeccionesFarmacología salivalMartin TC et al. · Journal of cardiothoracic and vascular anesthesia, 2024

Abstract

OBJECTIVES: To evaluate the safety of cangrelor administered concurrently with heparin or bivalirudin in patients on mechanical circulatory support. DESIGN: A single-center, retrospective cohort study of adult patients consecutively admitted between January 2016 and October 2020. SETTING: A tertiary medical center. PARTICIPANTS: Adult patients admitted to the cardiovascular intensive care unit put on mechanical circulatory support for acute myocardial infarction (AMI) or non-AMI indications. Patients who received cangrelor underwent percutaneous coronary intervention with stenting during the index event or within the last year. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The primary outcome was the incidence of major bleeding, defined by the Extracorporeal Life Support Organization criteria, in patients with mechanical circulatory support receiving cangrelor plus anticoagulation with heparin or bivalirudin with or without aspirin versus patients who did not receive cangrelor. Sixty-eight patients were included in the study. Twenty-nine patients received cangrelor, and 39 did not. Cangrelor was not associated with an increase in major bleeding; however, the CI was wide (adjusted hazard ratio 1.93, 95% CI 0.61-6.11; p = 0.262). CONCLUSIONS: Patients receiving cangrelor did not appear to be at higher risk of major bleeding compared to patients not receiving cangrelor. Larger trials should be conducted to better evaluate the safety of cangrelor in patients with mechanical circulatory support.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleComparative Study
Indexed MeSH termsHumansFemaleMaleRetrospective StudiesAdenosine MonophosphateMiddle AgedAnticoagulantsAgedHeart-Assist DevicesTreatment OutcomePeptide FragmentsHirudins

Resumen

To evaluate the safety of cangrelor administered concurrently with heparin or bivalirudin in patients on mechanical circulatory support.

Por qué esto importa para la hirudoterapia

This retrospective single-center cohort study evaluated the safety of adding cangrelor to anticoagulation (heparin or bivalirudin) in 68 patients on mechanical circulatory support, finding no significant increase in major bleeding with cangrelor use, though confidence intervals were wide. The study is a comparative pharmacology/safety analysis focused on antiplatelet-anticoagulant combinations in critically ill cardiac patients. Bivalirudin appears as one comparator anticoagulant. The abstract contains no mention of leeches, hirudotherapy, hirudin, or the leech secretome; it concerns antiplatelet and anticoagulant safety in mechanical circulatory support. There is no defensible relevance to ASH's domain, and this article is included only for completeness.

Citación

Comparison of Outcomes in Patients Requiring Mechanical Circulatory Support Who Received Cangrelor in Addition to Anticoagulation Versus Anticoagulation Alone

Martin TC et al. · Journal of cardiothoracic and vascular anesthesia, 2024

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.